CA-DIVERSIFIED-NANO
28.9.2018 14:52:06 CEST | Business Wire | Press release
Diversified Nano Solutions Corp launches revolutionary smartINK™ solutions to deliver the next generation of functional security printing to brand owners in any industry, institutions and individuals.
For the first time functional content printing and total security are delivered simultaneously and cost effectively by integrating copy-proof, unique and customer-specific smartQR™ biomarkers (watch video ) with the whole spectrum of digital inks.
Breakthrough smartINK ™ provides print and instant product identity and location tracking, at unbelievably low cost, on-the-spot, anywhere, anytime, by anyone.
Counterfeiting and illicit trade are pervasive in nearly every industry sector, harming consumers and brand owners, while costing the global economy over 1 trillion dollars annually.
Preservation of product and information integrity is increasingly important as sophisticated counterfeiting efforts easily defeat existing anti-counterfeit technologies.
smartINK™ makes it fun and easy to verify item integrity while establishing trust and defending item value. The smartINK™ solution scales easily, so individual brand owners and large enterprises alike can grow market share and successfully eliminate illicit trade and counterfeiting. Unbelievably low implementation costs enable fast payback and rapid deployment of secure mobile authentication and tracking worldwide.
As an expansion beyond digital print, DNSC is powering INKcrypt® smartQR™ available at www.goinkcrypt.com . FDA-compliant INKcrypt® smartQR™ enables tagging and marking of any physical object with traces of custom biomarkers using a variety of methods – including spray, brush, roll, flexo, offset and more.
Contact https://inkcryptink.com/ContactUs.aspx for details and to coordinate implementation of your smartINK™ and INKcrypt® smartQR™ solution.
smartINK™ solutions are compatible with inkjet platforms offered by Canon®, Screen®, Epson®, Ricoh®, HP®, FujiFilm®, Xerox®, Kyocera®, Konica Minolta® and more. Visit booth 829 at PRINT 18 September 30-October 2, 2018, in Chicago.
About DNSC
Diversified Nano Solutions Corporation (DNSC) , based in San Diego, California, specializes in developing, manufacturing and marketing high-performance inkjet inks and revolutionary, industry-unique smartINK™ solutions. Utilizing customer-specific INKcrypt® xDNA biomarker technology, smartINK™ provides total product & document security, proof of identity and worldwide tracking, anytime anywhere, at incredibly low cost. smartINK™ combines INKcrypt® xDNA™ biomarkers, the power of the internet and DNSC’s extensive product line of inks including CMYK , MICR (Magnetic Ink Character Recognition), invisible UV fluorescent / IR absorbing , spot and custom formulations .
Accessories and Security
DNSC supports its ink offerings with accessories to facilitate and aid x-nano™ ink use and smartINK™ solutions. These include specialty substrates, smartQR™ biomarker authentication testers, UV display lights, INKVERSE ™ “Infinite Ink Infuser” – a revolutionary and cost-effective way to adopt and deliver digital inks to existing and new inkjet systems via a continuous delivery ink supply system, and TransChrome ™ – an invisible color image generator to transform visible CMYK into invisible UV fluorescent red, green, blue, and white (RGBW) output, and more.
DNSC is presenting smartINK™ solutions, INKcrypt® smartQR™ and its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial and industrial inkjet space.
Visit us at booth 829 and discover the future of digital ink: functional, secure, trackable, differentiating!
View source version on businesswire.com: https://www.businesswire.com/news/home/20180928005061/en/
Contact:
For more information: Diversified Nano Solutions Corporation Linda Meyers US Headquarters: +1.858.924.1005 EMEA: +41.41 874 08 50 info@diversifiednano.com www.diversifiednano.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom